Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

Blood (2023) 142 (19): 1633–1646.

https://doi.org/10.1182/blood.2023019758

Published: 2023

Includes: Supplemental data

Journal Articles

Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells

Umair Munawar, Patrick Eiring, Cornelia Vogt, Larissa Haertle, Seungbin Han, Silvia Nerreter, Eva Teufel, Max Steinhardt, Xiang Zhou, Santiago Barrio, Hermann Einsele, Johannes M Waldschmidt, Leo Rasche, Markus Sauer, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 451.

https://doi.org/10.1182/blood-2023-180638

Published: 2023

Journal Articles

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Xiang Zhou, Vivien Wagner, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Mara John, Lukas Scheller, Umair Munawar, Seungbin Han, Johannes M Waldschmidt, Max S. Topp, Johannes Duell, Hermann Einsele, Angela Riedel, Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 95.

https://doi.org/10.1182/blood-2023-180534

Published: 2023

Journal Articles

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Natalia Buenache Cuenda, Hipolito Nicolas Cuesta Hernández, Alicia Giménez Sánchez, Laura Carneros Blanco, Juan Manuel Rosa-Rosa, Yanira Ruiz-Heredia, Enrique Revilla, Seungbin Han, Umair Munawar, Inmaculada Rapado, Rosa Ayala, K. Martin Kortüm, Antonio Valeri, Santiago Barrio, Joaquin Martinez Lopez, Larissa Haertle

Blood (2023) 142 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2023-184824

Published: 2023

Journal Articles

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Seungbin Han, Umair Munawar, Larissa Haertle, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Xiang Zhou, Max Steinhardt, Florian Eisele, Peter Raab, Marietta Truger, Sara Dorado, Santiago Barrio, Claudia Haferlach, Joaquin Martínez-López, Hermann Einsele, Leo Rasche, Johannes M Waldschmidt, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2023-181607

Published: 2023

Journal Articles

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Maximilian J Steinhardt, Patrick Eiring, Cornelia Vogt, Umair Munawar, Seungbin Han, Larissa Haertle, Silvia Nerreter, Eva Teufel, Julia Mersi, Xiang Zhou, Michael Hudecek, Joaquin Martinez-Lopez, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, Markus Sauer, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2023-189741

Published: 2023

Journal Articles

Clinical and Diagnostic Challenges in Patients with Concomitant Plasma Cell Disorders and Myeloproliferative Neoplasms

Maximilian J Steinhardt, Thomas Bumm, Xiang Zhou, Umair Munawar, Seungbin Han, Julia Mersi, Hermann Einsele, Leo Rasche, K. Martin Kortüm, Johannes M Waldschmidt

Blood (2023) 142 (Supplement 1): 6771.

https://doi.org/10.1182/blood-2023-189528

Published: 2023

Journal Articles

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Maximilian J Steinhardt, Max Bittrich, Xiang Zhou, Julia Noderer, Christine Riedhammer, Xianghui Xiao, Sophia Gawlas, Philipp Weis, Florian Eisele, Umair Munawar, Seungbin Han, Julia Mersi, Johannes M Waldschmidt, Hermann Einsele, Leo Rasche, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 6702.

https://doi.org/10.1182/blood-2023-189927

Published: 2023

Journal Articles

Bone Marrow Plasma Cell Infiltration Is a Prognostic Factor for Response to AL Amyloidosis Therapy

Maximilian J Steinhardt, Vladimir Cejka, Caroline Morbach, Aikaterini Papagianni, Silvia Nerreter, Cornelia Vogt, Umair Munawar, Seungbin Han, Leo Rasche, Johannes M Waldschmidt, Claudia Sommer, Stefan Störk, Hermann Einsele, K. Martin Kortüm

Blood (2023) 142 (Supplement 1): 6753.

https://doi.org/10.1182/blood-2023-189326

Published: 2023

Journal Articles

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12462–12463.

https://doi.org/10.1182/blood-2022-168694

Published: 2022

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Blood (2022) 140 (Supplement 1): 4230–4231.

https://doi.org/10.1182/blood-2022-169255

Published: 2022

Journal Articles

Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM

Blood (2022) 140 (Supplement 1): 4226–4227.

https://doi.org/10.1182/blood-2022-168702

Published: 2022

Journal Articles

Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma

Blood (2022) 140 (Supplement 1): 9987–9988.

https://doi.org/10.1182/blood-2022-166105

Published: 2022

Journal Articles

Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Blood (2022) 140 (Supplement 1): 4273–4274.

https://doi.org/10.1182/blood-2022-163848

Published: 2022

Journal Articles

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Xiang Zhou, Andrej Besse, Jessica Peter, Max Mendez Lopez, Larissa Haertle, Umair Munawar, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Hermann Einsele, Christoph Driessen, Martin Kortuem, Lenka Besse, Leo Rasche

Blood (2021) 138 (Supplement 1): 818.

https://doi.org/10.1182/blood-2021-147170

Published: 2021

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Santiago Barrio, PhD, Larissa Haertle, PhD, Umair Munawar, MSc, Lucia Martin, Isabel Cuenca, MSc, Cornelia Vogt, MSc, Andoni Garitano-Trojaola, PhD, Matteo Claudio Da Via', MD, Miguel Gallardo, PhD, Thorsten Stuehmer, PhD, Hermann Einsele, MD, Leo Rasche, MD, Joaquin Martinez-Lopez, MD PhD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 1807.

https://doi.org/10.1182/blood-2019-130812

Published: 2019

Journal Articles

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Larissa Haertle, PhD, Santiago Barrio, PhD, Michal Simicek, PhD, Umair Munawar, MSc, Ricardo Sanchez, PhD MD, Max Bittrich, MD, Matteo DaVia, MD, Cornelia Vogt, MSc, Nicola Giesen, MD, Andoni Garitano-Trojaola, PhD, Silvia Nerreter, Thorsten Stuehmer, PhD, Marc S. Raab, MD, Joaquin Martinez Lopez, MD PhD, Roman Hajek, MD, Hermann Einsele, MD, Leo Rasche, MD, Thomas Haaf, MD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 4349.

https://doi.org/10.1182/blood-2019-130847

Published: 2019

NARROW

Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis

Secondary Genetic Events Impact the Expression of Key Immunotargets on the Surface of Multiple Myeloma Cells

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma

Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma - a Direct Stochastic Optical Reconstruction Microscopy ( d STORM) Analysis in 53 Patients

Clinical and Diagnostic Challenges in Patients with Concomitant Plasma Cell Disorders and Myeloproliferative Neoplasms

Safety and Efficacy of Venetoclax Salvage Therapy in Relapsed/Refractory Multiple Myeloma with and without t(11;14)

Bone Marrow Plasma Cell Infiltration Is a Prognostic Factor for Response to AL Amyloidosis Therapy

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM

Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma

Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Clonal Competition Models to Understand Progression and Resistance in Myeloma

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only